Am J Physiol Cell Physiol AJP: Cell Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Cell Physiol 291: C995-C1001, 2006. First published June 14, 2006; doi:10.1152/ajpcell.00238.2006
0363-6143/06 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
291/5/C995    most recent
00238.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (11)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baker, K. M.
Right arrow Articles by Kumar, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baker, K. M.
Right arrow Articles by Kumar, R.

GROWTH, DIFFERENTIATION, AND APOPTOSIS

Intracellular angiotensin II induces cell proliferation independent of AT1 receptor

Kenneth M. Baker and Rajesh Kumar

Division of Molecular Cardiology, Cardiovascular Research Institute, The Texas A&M University System Health Science Center, College of Medicine; Scott & White; Central Texas Veterans Health Care System, Temple, Texas

Submitted 3 May 2006 ; accepted in final form 7 June 2006


   ABSTRACT
TOP
 ABSTRACT
METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
We recently reported intracrine effects of angiotensin II (ANG II) on cardiac myocyte growth and hypertrophy that were not inhibited by the ANG II type 1 receptor (AT1) antagonist, losartan. To further determine the role of AT1 in intracrine effects, we studied the effect of intracellular ANG II (iANG II) on cell proliferation in native Chinese hamster ovary (CHO) cells and those stably transfected with AT1 receptor (CHO-AT1). CHO-AT1, but not CHO cells, showed enhanced proliferation following exposure to extracellular ANG II (eANG II). However, when transiently transfected with an iANG II expression vector, both cell types showed significantly enhanced proliferation, compared with those transfected with a scrambled peptide. Losartan blocked eANG II-induced cell proliferation, but not that induced by iANG II. To further confirm these findings, CHO and CHO-AT1 cells were stably transfected for iANG II expression (CHO-iA and CHO-AT1-iA, respectively). Cells grown in serum-free medium were counted every 24 h, up to 72 h. CHO-iA and CHO-AT1-iA cells showed a steeper growth curve compared with CHO and CHO-AT1, respectively. These observations were confirmed by Wst-1 assay. The AT1 receptor antagonists losartan, valsartan, telmisartan, and candesartan did not attenuate the faster growth rate of CHO-iA and CHO-AT1-iA cells. eANG II showed an additional growth effect in CHO-AT1-iA cells, which could be selectively blocked by losartan. These data demonstrate that intracrine ANG II can act independent of AT1 receptors and suggest novel intracellular mechanisms of action for ANG II.

renin-angiotensin system; angiotensinogen; peptide hormones; nuclear signaling; intracrine

ANGIOTENSIN II (ANG II), the principal effector peptide of the renin-angiotensin system, has pleiotropic effects in multiple tissues (34). It has a central role in cardiovascular homeostasis and is implicated in the development of cardiac, vascular and renal pathologies. ANG II is formed in the circulation or locally in various tissues, through a cascade of reactions from components of local and/or systemic origin (12, 23). Thus, it acts as an endocrine, as well as an autocrine/paracrine peptide hormone. ANG II mediates effects through two types of receptors, AT1 and AT2, which are both seven-transmembrane G protein-coupled receptors (3). The AT1 receptor accounts for the majority of the known functions of ANG II in various tissues. Binding of ANG II to AT1 results in internalization of the AT1-ANG II complex (2, 6, 43). While the receptor is recycled back to plasma membrane, ANG II is destined for intracellular locations such as lysosomes and the nucleus (14, 21, 44). The presence of ANG II binding sites on the nuclear membrane suggests a functional role for intracellular ANG II (4, 41). In addition to internalization in a complex with the receptor, the possibility of intracellular synthesis of ANG II has also been suggested by several studies (10, 32, 45). The existence of nuclear ANG II binding sites and intracellular ANG II (iANG II) strongly suggests a functional consequence. The possible clinical relevance of iANG II is particularly evident in the human diabetic condition, wherein intracellular staining for ANG II in heart is significantly increased compared with the nondiabetic state (18). We thus determined the functionality of iANG II and demonstrated that iANG II exerted biological, intracrine effects (1). We expressed ANG II intracellularly in myocytes, for both in vitro and in vivo studies. Overexpression of iANG II in cultured neonatal rat ventricular myocytes caused hypertrophic cellular growth. Cardiac-specific overexpression of iANG II in mouse resulted in biventricular cardiac hypertrophy. Significantly, the AT1 receptor blocker losartan did not block the hypertrophic intracrine effects of iANG II. The lack of effect of losartan indicated that either losartan did not gain access to the intracellular compartment, or an AT1-independent intracellular mechanism was operative. In this study, we determined the requirement for AT1 receptors in the intracrine effects of ANG II. We used Chinese hamster ovary (CHO)-K1 cells as a model to address this question because these cells express little AT1 receptor and do not respond to exogenous ANG II. These cells were stably transfected to express AT1 receptor and iANG II. The growth properties of AT1 and/or iANG II-expressing cells were compared with those of nonexpressing cells, to determine the requirement for AT1 receptors in the intracrine effects of iANG II.


   METHODS
TOP
 ABSTRACT
 METHODS
RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Cell culture. CHO cells were cultured in Ham's F-12K medium (Invitrogen) containing 10% FBS (Sigma), 100 U/ml penicillin, and 100 µg/ml streptomycin. Cells were transferred to serum- and antibiotic-free medium before performing the growth studies.

iANG II expression vector. The iANG II expression cassette (pcDNA/TO-iAng II) was similar to that which has been previously described for adenoviral expression of iANG II (1). Briefly, two complimentary oligonucleotides containing the coding sequence for the eight amino acids of ANG II, start and stop codons, and flanked by BamHI and XbaI sites (sense strand: 5'-GATCCATGGACCGCGTATACATCCACCCCTTTTAAT-3'), were annealed and cloned into the pcDNA4/TO vector (Invitrogen). The coding sequence was flanked on the 5'-side by a complete cytomegalovirus enhancer-promoter sequence, containing two copies of the tetracycline operator TetO 2 sequence, and by a 225 bp bovine growth hormone polyadenylation sequence on the 3'-side. A control vector was similarly generated, containing the scrambled ANG II peptide coding sequence (sense strand: 5'-GATCCATGTACGACCACCGCGTATTTCCCATCTAG-3').

Transient transfection. Cells were seeded in 96-well plates at a density of 5 x 104 cells per well and grown overnight. Cells were transfected with the control or iANG II expression plasmid using Lipofectamine 2000 (Invitrogen) in serum-free medium for 4 h, followed by serum-containing medium overnight. The following day, transfected cells were transferred to serum-free medium or serum-free medium containing drugs, as described below.

Generation of stable cell lines. CHO cells stably transfected with rat AT1a wild-type receptor (CHO-AT1) were obtained from Dr. Junichi Sadoshima (The University of Medicine and Dentistry of New Jersey) (38). CHO and CHO-AT1 cells were stably transfected with pcDNA/TO-iANG II using lipofectamine reagent. Stable clones (CHO-iA and CHO-AT1-iA, respectively) were selected by neomycin and zeocin resistance. Production of ANG II in cell lysates and in the medium of these cells was measured using a competitive ELISA, as previously described (36).

Radioligand binding assay. AT1 receptor expression was quantified by a competitive binding assay. Cells were seeded in 24-well plates at a density of 1.25 x 105 cells per well and grown overnight. Binding buffer [Dulbecco's PBS with 2% BSA and 10 µg/ml bacitracin (Sigma)] containing 0.25 nmol/l [3-iodotyrosyl4-125I]ANG II (Perkin Elmer) and varying concentrations of unlabeled ANG II (0–1,000 nmol/l) was added to cells in a volume of 250 µl and incubated at 37°C for 60 min. Binding was terminated by aspirating the binding solution and washing the cells three times with 0.5 ml of ice-cold PBS. Cells were solubilized in 250 µl of lysis buffer (0.25 N NaOH, 0.05% SDS) and counts determined using a gamma-counter (Hewlett-Packard). The Bmax and Kd were calculated using Prism 3.03 software (GraphPad). Protein was determined using Bio-Rad's DC protein assay kit.

Cell proliferation. Cell proliferation was determined using two methods: 1) the Wst-1 assay (Roche), which measures metabolic activity of the cells and, 2) by counting cells with a Coulter counter (Beckman). For the Wst-1 assay, transiently transfected cells were grown in serum-free medium or serum-free medium containing AT1 blockers [10–6 mol/l, losartan (Merck), valsartan (Novartis), candesartan (AstraZeneca), or telmisartan (Boehringer-Ingelheim), as described for each figure] or extracellular ANG II (eANG II, 1 x 10–7 mol/l) and cell proliferation measured 48 h thereafter. After the medium was removed, 100 µl per well of 10% Wst-1 (in serum-free medium) was added to the cells. The plates were preread immediately on a plate reader at 450 nm to obtain a background count. After incubation at 37°C for 30 min, the plates were read again to determine the color density, which was proportional to the number of the cells. For stably transfected cells, the cells were seeded in 96-well plates at a density of 1.5 x 104 cells per well. The following day, medium was changed to serum-free medium and the Wst-1 assay performed on one set of cells to obtain time 0 values. Other sets of cells were incubated in fresh serum-free medium with or without drugs or eANG II (as described above) and the Wst-1 assay performed every 24 h, until 72 h. To determine cell proliferation by counting cell numbers, the stably transfected cells were seeded in growth medium (F12-K) containing 10% FBS in 24-well plates at a density of 6.25 x 104 cells per well. After 24 h, the medium was replaced with serum-free medium and one set of cells counted with a Coulter counter after trypsinization and resuspension in PBS. This represented the time 0 cell count. Similarly, for other sets of cells, medium was replaced with or without additives, and cells were counted every 24 h, up to 72 h.

Statistical analysis. Values are expressed as means ± SE. ANOVA with Tukey's post hoc test was used for statistical analysis. P < 0.05 was considered statistically significant.


   RESULTS
TOP
 ABSTRACT
 METHODS
 RESULTS
DISCUSSION
 GRANTS
 REFERENCES
 
AT1 expression in CHO cells. Radioligand binding assay showed that CHO cells expressed very little ANG II receptor (16 ± 5 fmol/mg protein, Fig. 1B), while stably transfected CHO-AT1 cells showed high levels of AT1 as expected (5,399 ± 1,229 fmol/mg protein, Fig. 1A). The binding of the labeled ANG II to the cells was completely blocked by losartan, but not by the AT2 antagonist PD123319, suggesting that these cells expressed only AT1 receptor (Fig. 1, C and D). Similarly, the observation of low or undetectable levels of AT1 receptors in CHO cells, which do not couple to ANG II-induced responses (inositol phosphate production, thymidine incorporation, and cell division), has been reported by other investigators (30, 42).


Figure 1
View larger version (16K):
[in this window]
[in a new window]
  		Fig. 1. ANG II receptor binding assay on Chinese hamster ovary (CHO) and CHO stably transfected with AT1 receptor (CHO-AT1) cells. A: binding on CHO-AT1 cells. B: binding on CHO cells. C and D: total binding in the presence of ANG II (1 µmol/l), losartan (1 µmol/l), or PD123319 (1 µmol/l) on CHO-AT1 cells, and CHO cells, respectively. A competitive radioligand binding assay was performed with 0.25 nmol/l [125I]ANG II for 1 h, at room temperature, in the presence of varying concentrations of unlabeled ANG II. The assay was performed in duplicate and repeated at least three times. Data were subjected to nonlinear regression analysis. The results are from a representative experiment, expressed as percentages of specific (A and B) or total (C and D) [125I]ANG II bound.

 
Intracellular ANG II expression in CHO and CHO-AT1 cells. Because CHO cells might not produce the necessary enzymes for processing of angiotensinogen to ANG II, the ANG II expression vector, pcDNA/TO-iANG II, contained sequence that coded for the mature ANG II peptide without a secretory signal. We performed experiments with both transiently and stably transfected cells. Production of ANG II in these cells was measured by a competitive ELISA in cell lysates, as well as in culture medium. Stable clones expressing similar levels of ANG II (CHO-iA, 119 ± 6; CHO-AT1-iA, 91 ± 3 pg/mg protein) were chosen for the study. The iANG II concentration in stably transfected cells is similar to that reported in lysates of human hyperglycemic mesangial cells (25) and rat cardiac myocytes (our unpublished observations). No ANG II was detected in naïve CHO cells or the culture medium of transfected cells, as we previously reported in cardiac myocytes (1), indicating that it was retained intracellularly. Intracellular generation of functional, recombinant short peptides, has previously been described by others (27, 28).

Effect of intra- and extra-cellular ANG II on cell proliferation. CHO and CHO-AT1 cells were transiently transfected with control (scrambled ANG II) or pcDNA/TO-iANG II. For controls, cells were exposed to eANG II (10–7 mol/l) after being incubated in serum-free medium for 12 h. eANG II did not enhance growth in CHO cells (Fig. 2A), but resulted in a 55 ± 15% increase in proliferation in CHO-AT1 cells (Fig. 2B). This is consistent with the requirement of AT1 for eANG II effects. However, iANG II resulted in cell proliferation in both CHO and CHO-AT1 cells (Fig. 2). iANG II-induced cell proliferation was not statistically different than that induced by eANG II. To determine whether an AT1 receptor blocker could inhibit the ANG II-induced cell proliferation, losartan (1 x 10–6 mol/l) was included in the culture medium. As shown in Fig. 2, losartan completely blocked the effects of eANG II in CHO-AT1 cells, but not the effects of iANG II in either cell type. These data suggest that CHO cells have 1) cellular machinery to induce intracrine effects and are a suitable model to study intracrine mechanisms, and 2) that AT1 is not required for intracrine effects of ANG II.


Figure 2
View larger version (16K):
[in this window]
[in a new window]
  		Fig. 2. Transient expression of intracellular ANG II (iANG II) in CHO and CHO-AT1 cells increases proliferation. The cells, CHO (A) and CHO-AT1 (B), were transfected in 96-well dishes with a scrambled ANG II control (Cont), or iANG II expression vector, using Lipofectamine 2000. Transfected cells were transferred to serum-free medium, with or without losartan (Los) after 12 h of incubation. Wst-1 reagent was added 48 h thereafter to the culture medium and color formation measured at 450 nm using a plate reader. eANG II (100 nmol/l) was added to nontransfected cells after 12 h of incubation in serum-free medium. Data are expressed as means ± SE of 5 separate experiments, *P < 0.05 vs. Cont.

 
Stable transfection of CHO and CHO-AT1 Cells for iANG II expression. To further confirm the intracrine growth effects of iANG II, a growth curve of stable iANG II-expressing cells was determined after transferring the cells to serum-free medium. As shown in Fig. 3A, iANG II-expressing cells, CHO-iA (top) and CHO-AT1-iA (bottom), proliferated at a significantly faster rate compared with the corresponding nonexpressing CHO and CHO-AT1 cells, as determined by cell counts. These observations were confirmed by measuring cell proliferation using the Wst-1 assay (Fig. 3B, top and bottom).


Figure 3
View larger version (14K):
[in this window]
[in a new window]
  		Fig. 3. Stable expression of iANG II in CHO and CHO-AT1 cells increases the proliferation rate, as determined by cell counts and Wst-1 assay. A: The stable iANG II-expressing cells, CHO-iA (top) and CHO-AT1-iA (bottom), and parent cells CHO (top) and CHO-AT1 (bottom), were seeded in 24-well dishes and transferred to serum-free medium after 24 h. Cell number was determined using a Coulter counter, at the time of placement in serum-free medium (time 0) and every 24 h thereafter, up to 72 h. B: Cells were seeded in 96-well dishes, transferred to serum-free medium after 24 h, and cell proliferation was measured by Wst-1 assay at time 0 and every 24 h thereafter, up to 72 h. Data are expressed as means ± SE; N = 6; *P < 0.05.

 
Effect of AT1 receptor blockers on growth rate of stably transfected cells. In stably transfected cells, as with transient expression, the AT1 antagonist valsartan did not attenuate the faster growth rate of iANG II-expressing cells, but completely blocked the effect of eANG II (Fig. 4). In a separate experiment, we tested several AT1 blockers, candesartan, losartan, telmisartan, and valsartan, to determine whether the different lipophilicities of these inhibitors would have any effect. None of the antagonists inhibited the intracrine effects of ANG II in either CHO-iA or CHO-AT1-iA cells (Fig. 5).


Figure 4
View larger version (15K):
[in this window]
[in a new window]
  		Fig. 4. The AT1 receptor blocker, valsartan, inhibits extracellular ANG II (eANG II), but not iANG II, -induced cell proliferation. The experiment was performed as described in Fig. 3A. Valsartan (Val, 1 µmol/l) and/or eANG II (100 nmol/l) was added to the culture medium when cells were transferred to serum-free medium. The medium with the additives was replaced every 24 h. The results are expressed as relative cell numbers, after 72 h of Cont (non-iANG II-expressing cells), iANG II (iANG II-expressing cells), or eANG II (Cont in presence of 100 nmol/l ANG II). A: CHO cells. B: CHO-AT1 cells. Data are expressed as means ± SE; N = 6; *P < 0.05 vs. Cont.

 

Figure 5
View larger version (16K):
[in this window]
[in a new window]
  		Fig. 5. Effect of different AT1 receptor blockers on iANG II- induced cell proliferation. The experiment was performed as described in Fig. 3B. Angiotensin receptor blockers [candesartan (Candi), Los, telmisartan (Telmi), and Val, 1 µmol/l] were added to the culture medium when cells were transferred to serum-free medium. The medium with the additives was replaced every 24 h. The results are expressed as relative optical density, after 72 h in the serum-free medium. A: CHO and CHO-iA cells. B: CHO-AT1 and CHO-AT1-iA cells. Data are expressed as means ± SE; N = 6; *P < 0.05.

 
Additive effects of intra- and extracellular ANG II. Because only extracellular and not intracellular effects of ANG II are blocked by AT1 receptor antagonists, we hypothesized that together, extra- and intracellular ANG II would produce an additive effect. Indeed, eANG II produced further growth in CHO-AT1-iA cells compared with CHO-AT1 cells. The additional growth effect induced by eANG II in CHO-AT1-iA cells could be selectively blocked by AT1 antagonists (Fig. 6).


Figure 6
View larger version (12K):
[in this window]
[in a new window]
  		Fig. 6. Additive effect of eANG II and selective inhibition of the eANG II effect, by valsartan, in CHO-AT1 cells. The experiment was performed with CHO-AT1 cells as described in Fig. 4. Data are expressed as means ± SE; N = 6; *P < 0.05 vs. Cont, **P < 0.05 vs. iANG II and eANG II.

 

   DISCUSSION
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
GRANTS
 REFERENCES
 
In this report we demonstrate that AT1 receptor is not required for the intracrine effects of ANG II. Intracrine effects of ANG II in cardiac myocytes and other cells have previously been reported (1, 5, 9, 11, 15, 16, 20, 46). It has been proposed that the intracrine effects of ANG II are mediated by an intracellular/nuclear AT1 or AT1-like receptor. However, AT1 antagonists have shown mixed efficacy in blocking intracellular effects of ANG II. In hamster cardiac myocytes, gap junction conduction was blocked by intracellular losartan, but not the inward Ca2+ current in rat and hamster myocytes (10, 11). In the A7r5 smooth muscle cell line, cellular growth promoted by iANG II showed limited sensitivity to an AT1 antagonist (17). In our earlier studies with cardiac myocytes, losartan did not block intracrine ANG II-induced cell growth. Neither did the antagonist inhibit cardiac hypertrophy in mice with cardiac-specific expression of iANG II. Thus the requirement for AT1 in intracrine effects of ANG II is not clear. Here, we determined if iANG II could act without AT1 receptors.

CHO cells have been extensively used to study the signaling mechanisms of specific AT1 receptor subtypes, because these cells express little or undetectable plasma membrane AT1 receptor (30, 42). Intracellular AT1 receptor was also not detected in the CHO cells (19). Expression of iANG II did not increase radioligand binding in CHO-iA cells, compared with CHO cells (data not shown), indicating that iANG II did not upregulate endogenous AT1 receptor. Consistent with that, eANG II did not elicit any biological effect in CHO cells, as shown above and by others (30, 42). However, when transfected with a plasmid that encodes for iANG II peptide, both CHO and CHO-AT1 cells showed significantly enhanced proliferation. This plasmid contained the same expression cassette that we had used earlier in studies with cardiac myocytes (1). The iANG II concentration in the cells was comparable to that reported in human hyperglycemic mesangial cells (25), cardiac myocytes (our unpublished data), and in other studies with iANG II (7). The recombinant ANG II is retained inside the cells and is not detectable in the culture medium. Interestingly, iANG II-induced cell proliferation in CHO cells was not significantly different from that in CHO-AT1 cells, further suggesting no dependence of the intracrine mechanism on AT1.

This observation is in contrast to that of Cook et al. (8), who reported that iANG II increased mitogenic index in CHO cells only when iANG II is co-transfected with the AT1 receptor construct. The discrepancy between the two observations could be related to a number of explanations. Cook et al. performed transient transfection, followed by incubation of the cells in a medium containing 2% serum and then determined mitogenic index or cell numbers. The presence of serum may have masked the intracellular effects of ANG II. The second possibility lies in the fact that they expressed iANG II as a fusion protein with cyan fluorescent protein (ECFP), whereas our expression cassette produced native ANG II peptide, with only a single extra methionine at the NH2 terminus. Although, in their case, fusion of ANG II with ECFP did not prevent interaction with AT1 receptor and AT1-mediated effects, this could have affected possible interactions of ANG II with chromatin or other putative intracellular substrates. The use of serum, and the use of ANG II in a fusion protein might explain why they did not observe a mitogenic effect of iANG II, in the absence of AT1 receptors.

We did not observe an inhibitory effect of extracellular losartan on intracrine ANG II-induced cell proliferation, which was in agreement with other studies in cardiac myocytes (10, 15). AT1 antagonists differ in pharmacological properties, such as lipophilicity and surmountability, which might influence intracellular efficacy (29). Although there is no direct evidence for cellular internalization, intracellular efficacy of angiotensin receptor blockers (ARBs) was demonstrated by the effect on peroxisome proliferator-activated receptor-{gamma} activation (37). The latter correlated with the degree of lipophilicity among ARBs and was not dependent on internalization via AT1 receptor (37). We tested four different AT1 antagonists to determine if more lipophilicity would block intracrine effects of iANG II. Even telmisartan, which is insurmountable and the most lipophilic (26), was not effective. We could not test higher concentrations of the ARBs because of a nonspecific effect on cell growth. However, Cook et al. (8) could inhibit intracrine effects of ANG II in CHO cells, when iANG II was co-transfected with AT1, using the same concentration of extracellular losartan. Again, the possible explanation lies in the fusion iANG II construct used in the study, which could possibly produce only AT1-mediated effects, as discussed above.

If iANG II action is independent of AT1 receptors, then why was losartan effective in inhibiting the intracrine effects in some studies (10)? An analysis of earlier studies with iANG II has suggested interaction with multiple intracellular receptors/proteins that couple to different intracrine effects (17). It is likely that involvement of AT1 receptors depends on the functional parameter studied, how ANG II originates inside the cells, and the subcellular location of agonist. Various techniques; microinjection, liposome-mediated delivery, and intracellular synthesis by a recombinant approach, have been used with iANG II (1, 9, 10, 16, 20). Our method of intracellular generation of minimally altered recombinant ANG II demonstrates that the AT1 receptor is not required for intracrine effects.

In accordance with our hypothesis for two different mechanisms, AT1-dependent and -independent, for hormonal and intracrine effects of ANG II, respectively, we observed an additive effect on cell proliferation when ANG II was present, both inside and outside of the cells. The AT1 antagonist valsartan selectively blocked only the extracellular effects. The signaling pathways activated by eANG II appear to be more potent than the intracellular mechanism, as evidenced by the greater cell proliferation induced by eANG II (Fig. 4). We did not see a significant difference in proliferation rate induced by iANG II in CHO and CHO-AT1 cells.

The nature of a possible AT1-independent intracrine mechanism for ANG II is not clear. A plausible explanation seems to be a direct effect of ANG II on chromatin and gene expression, as suggested by the work of Re et al. (33, 35). Intranuclear localization of ANG II after AT1-mediated internalization or intracellular synthesis, and direct binding to chromatin and an effect on gene expression (8, 13, 14, 33, 35), are all findings in support of this hypothesis. Insulin, PDGF, and FGF-2 also demonstrate an intracrine mode of action and can associate with chromatin, suggesting a direct modulation of chromatin structure and gene expression (22). FGF-2 was recently shown to directly interact with upstream binding factor, an architectural transcription factor in the nucleus, which regulates rRNA transcription (39). Thus involvement of novel intracellular receptors or proteins in intracrine effects of ANG II represents an attractive hypothesis.

This is the first report to demonstrate ANG II activity in the absence of "known" receptors for the peptide. Together with other studies, these findings suggest that intracrine ANG II can act with and without AT1 receptor. ARBs have been reported to block hormonal, as well as AT1-dependent intracrine effects of ANG II (17). However, these drugs do not inhibit AT1-independent intracrine effects. The physiological significance of such effects is not directly evident from this study, but is suggested by several recent reports. Intracellular ANG II levels are increased in the diabetic human heart (18). High glucose increases intracellular renin activity in rat mesangial cells, and thus ANG II generation (45). In human mesangial cells high glucose increased intracellular ANG II, but not in the medium (25). In "The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study," hypertensive patients with diabetes showed less regression of left ventricular hypertrophy and higher cardiovascular morbidity and mortality, than patients without diabetes, in response to antihypertensive therapy that included the AT1 antagonist losartan (31). These studies suggest a role for intracrine ANG II in diabetes, that may not be blocked by AT1 antagonists. Thus the intracrine system might be selectively activated in association with certain conditions and/or cell types (24, 40), thereby contributing to various pathological conditions. Identification of intracrine ANG II mechanisms may lead to the development of molecular or pharmacological interventions that could be targeted to specific renin-angiotensin system compartments.


   GRANTS
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
REFERENCES
 
This work was supported by American Heart Association, Texas Affiliate, Beginning Grant-In-Aid (to R. Kumar).


   FOOTNOTES
 

Address for reprint requests and other correspondence: R. Kumar, Cardiovascular Research Institute, The Texas A&M Univ. System HSC, 1901 South 1st St., Bldg. 205, Temple, TX 76504 (e-mail: kumar{at}medicine.tamhsc.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   REFERENCES
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
1. Baker KM, Chernin MI, Schreiber T, Sanghi S, Haiderzaidi S, Booz GW, Dostal DE, and Kumar R. Evidence of a novel intracrine mechanism in angiotensin II-induced cardiac hypertrophy. Regul Pept 120: 5–13, 2004.[CrossRef][ISI][Medline]

2. Bkaily G, Sleiman S, Stephan J, Asselin C, Choufani S, Kamal M, Jacques D, Gobeil F Jr, and D'Orleans-Juste P. Angiotensin II AT1 receptor internalization, translocation and de novo synthesis modulate cytosolic and nuclear calcium in human vascular smooth muscle cells. Can J Physiol Pharmacol 81: 274–287, 2003.[CrossRef][ISI][Medline]

3. Booz GW and Baker KM. Intracellular Signaling and the Cardiac Renin Angiotensin System. West Sussex, UK: Wiley, 2004.

4. Booz GW, Conrad KM, Hess AL, Singer HA, and Baker KM. Angiotensin-II-binding sites on hepatocyte nuclei. Endocrinology 130: 3641–3649, 1992.[Abstract]

5. Brailoiu E, Filipeanu CM, Tica A, Toma CP, de Zeeuw D, and Nelemans SA. Contractile effects by intracellular angiotensin II via receptors with a distinct pharmacological profile in rat aorta. Br J Pharmacol 126: 1133–1138, 1999.[CrossRef][ISI][Medline]

6. Chen R, Mukhin YV, Garnovskaya MN, Thielen TE, Iijima Y, Huang C, Raymond JR, Ullian ME, and Paul RV. A functional angiotensin II receptor-GFP fusion protein: evidence for agonist-dependent nuclear translocation. Am J Physiol Renal Physiol 279: F440–F448, 2000.[Abstract/Free Full Text]

7. Cook JL, Giardina JF, Zhang Z, and Re RN. Intracellular angiotensin II increases the long isoform of PDGF mRNA in rat hepatoma cells. J Mol Cell Cardiol 34: 1525–1537, 2002.[CrossRef][ISI][Medline]

8. Cook JL, Re R, Alam J, Hart M, and Zhang Z. Intracellular angiotensin II fusion protein alters AT1 receptor fusion protein distribution and activates CREB. J Mol Cell Cardiol 36: 75–90, 2004.[CrossRef][ISI][Medline]

9. Cook JL, Zhang Z, and Re RN. In vitro evidence for an intracellular site of angiotensin action. Circ Res 89: 1138–1146, 2001.[Abstract/Free Full Text]

10. De Mello WC. Further studies on the effect of intracellular angiotensins on heart cell communication: on the role of endogenous angiotensin II. Regul Pept 115: 31–36, 2003.[CrossRef][ISI][Medline]

11. De Mello WC. Intracellular angiotensin II regulates the inward calcium current in cardiac myocytes. Hypertension 32: 976–982, 1998.[Abstract/Free Full Text]

12. Dostal DE and Baker KM. The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function? Circ Res 85: 643–650, 1999.[Abstract/Free Full Text]

13. Eggena P, Zhu JH, Clegg K, and Barrett JD. Nuclear angiotensin receptors induce transcription of renin and angiotensinogen mRNA. Hypertension 22: 496–501, 1993.[Abstract/Free Full Text]

14. Erdmann B, Fuxe K, and Ganten D. Subcellular localization of angiotensin II immunoreactivity in the rat cerebellar cortex. Hypertension 28: 818–824, 1996.[Abstract/Free Full Text]

15. Eto K, Ohya Y, Nakamura Y, Abe I, and Iida M. Intracellular angiotensin II stimulates voltage-operated Ca2+ channels in arterial myocytes. Hypertension 39: 474–478, 2002.[Abstract/Free Full Text]

16. Filipeanu CM, Henning RH, de Zeeuw D, and Nelemans A. Intracellular angiotensin II and cell growth of vascular smooth muscle cells. Br J Pharmacol 132: 1590–1596, 2001.[CrossRef][ISI][Medline]

17. Filipeanu CM, Henning RH, Nelemans SA, and de Zeeuw D. Intracellular angiotensin II: from myth to reality? J Renin Angiotensin Aldosterone Syst 2: 219–226, 2001.[Free Full Text]

18. Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A, Nadal-Ginard B, and Anversa P. Myocardial cell death in human diabetes. Circ Res 87: 1123–1132, 2000.[Abstract/Free Full Text]

19. Giles ME, Fernley RT, Nakamura Y, Moeller I, Aldred GP, Ferraro T, Penschow JD, McKinley MJ, and Oldfield BJ. Characterization of a specific antibody to the rat angiotensin II AT1 receptor. J Histochem Cytochem 47: 507–516, 1999.[Abstract/Free Full Text]

20. Haller H, Lindschau C, Erdmann B, Quass P, and Luft FC. Effects of intracellular angiotensin II in vascular smooth muscle cells. Circ Res 79: 765–772, 1996.[Abstract/Free Full Text]

21. Hein L, Meinel L, Pratt RE, Dzau VJ, and Kobilka BK. Intracellular trafficking of angiotensin II and its AT1 and AT2 receptors: evidence for selective sorting of receptor and ligand. Mol Endocrinol 11: 1266–1277, 1997.[Abstract/Free Full Text]

22. Jans DA and Hassan G. Nuclear targeting by growth factors, cytokines, and their receptors: a role in signaling? Bioessays 20: 400–411, 1998.[CrossRef][ISI][Medline]

23. Kurdi M, De Mello WC, and Booz GW. Working outside the system: an update on the unconventional behavior of the renin-angiotensin system components. Int J Biochem Cell Biol 37: 1357–1367, 2005.[CrossRef][ISI][Medline]

24. Lavoie JL, Liu X, Bianco RA, Beltz TG, Johnson AK, and Sigmund CD. Evidence supporting a functional role for intracellular renin in the brain. Hypertension 47: 461–466, 2006.[Abstract/Free Full Text]

25. Leehey DJ, Isreb MA, Marcic S, Singh AK, and Singh R. Effect of high glucose on superoxide in human mesangial cells: role of angiotensin II. Nephron Exp Nephrol 100: e46–e53, 2005.[CrossRef][Medline]

26. Maillard MP, Perregaux C, Centeno C, Stangier J, Wienen W, Brunner HR, and Burnier M. In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist. J Pharmacol Exp Ther 302: 1089–1095, 2002.[Abstract/Free Full Text]

27. Matza-Porges S, Horresh I, Tavor E, Panet A, and Honigman A. Expression of an anti apoptotic recombinant short peptide in mammalian cells. Apoptosis 10: 987–996, 2005.[CrossRef][ISI][Medline]

28. Matza-Porges S, Tavor E, Panet A, and Honigman A. Intracellular expression of a functional short peptide confers resistance to apoptosis. Exp Cell Res 290: 60–67, 2003.[CrossRef][ISI][Medline]

29. Morsing P, Adler G, Brandt-Eliasson U, Karp L, Ohlson K, Renberg L, Sjoquist PO, and Abrahamsson T. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. Hypertension 33: 1406–1413, 1999.[Abstract/Free Full Text]

30. Ohnishi J, Ishido M, Shibata T, Inagami T, Murakami K, and Miyazaki H. The rat angiotensin II AT1A receptor couples with three different signal transduction pathways. Biochem Biophys Res Commun 186: 1094–1101, 1992.[CrossRef][ISI][Medline]

31. Okin PM, Devereux RB, Gerdts E, Snapinn SM, Harris KE, Jern S, Kjeldsen SE, Julius S, Edelman JM, Lindholm LH, and Dahlof B. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. Circulation 113: 1588–1596, 2006.[Abstract/Free Full Text]

32. Peters J, Farrenkopf R, Clausmeyer S, Zimmer J, Kantachuvesiri S, Sharp MGF, and Mullins JJ. Functional significance of prorenin internalization in the rat heart. Circ Res 90: 1135–1141, 2002.[Abstract/Free Full Text]

33. Re R and Parab M. Effect of angiotensin II on RNA synthesis by isolated nuclei. Life Sci 34: 647–651, 1984.[CrossRef][ISI][Medline]

34. Re RN. Tissue renin angiotensin systems. Med Clin North Am 88: 19–38, 2004.[CrossRef][ISI][Medline]

35. Re RN, Vizard DL, Brown J, and Bryan SE. Angiotensin II receptors in chromatin fragments generated by micrococcal nuclease. Biochem Biophys Res Commun 119: 220–227, 1984.[CrossRef][ISI][Medline]

36. Sanghi S, Kumar R, Smith M, Baker KM, and Dostal DE. Activation of protein kinase A by atrial natriuretic peptide in neonatal rat cardiac fibroblasts: role in regulation of the local renin-angiotensin system. Regul Pept 132: 1–8, 2005.[CrossRef][ISI][Medline]

37. Schupp M, Janke J, Clasen R, Unger T, and Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109: 2054–2057, 2004.[Abstract/Free Full Text]

38. Seta K, Nanamori M, Modrall JG, Neubig RR, and Sadoshima J. AT1 receptor mutant lacking heterotrimeric G protein coupling activates the Src-Ras-ERK pathway without nuclear translocation of ERKs. J Biol Chem 277: 9268–9277, 2002.[Abstract/Free Full Text]

39. Sheng Z, Liang Y, Lin CY, Comai L, and Chirico WJ. Direct regulation of rRNA transcription by fibroblast growth factor 2. Mol Cell Biol 25: 9419–9426, 2005.[Abstract/Free Full Text]

40. Sherrod M, Liu X, Zhang X, and Sigmund CD. Nuclear localization of angiotensinogen in astrocytes. Am J Physiol Regul Integr Comp Physiol 288: R539–R546, 2005.[Abstract/Free Full Text]

41. Tang SS, Rogg H, Schumacher R, and Dzau VJ. Characterization of nuclear angiotensin-II-binding sites in rat liver and comparison with plasma membrane receptors. Endocrinology 131: 374–380, 1992.[Abstract]

42. Teutsch B, Bihoreau C, Monnot C, Bernstein KE, Murphy TJ, Alexander RW, Corvol P, and Clauser E. A recombinant rat vascular AT1 receptor confers growth properties to angiotensin II in Chinese hamster ovary cells. Biochem Biophys Res Commun 187: 1381–1388, 1992.[CrossRef][ISI][Medline]

43. Thomas WG, Thekkumkara TJ, and Baker KM. Cardiac effects of AII. AT1A receptor signaling, desensitization, and internalization. Adv Exp Med Biol 396: 59–69, 1996.[Medline]

44. van Kats JP, de Lannoy LM, Jan Danser AH, van Meegen JR, Verdouw PD, and Schalekamp MA. Angiotensin II type 1 (AT1) receptor-mediated accumulation of angiotensin II in tissues and its intracellular half-life in vivo. Hypertension 30: 42–49, 1997.[Abstract/Free Full Text]

45. Vidotti DB, Casarini DE, Cristovam PC, Leite CA, Schor N, and Boim MA. High glucose concentration stimulates intracellular renin activity and angiotensin II generation in rat mesangial cells. Am J Physiol Renal Physiol 286: F1039–F1045, 2004.[Abstract/Free Full Text]

46. Zhuo JL, Li XC, Garvin JL, Navar LG, and Carretero OA. Intracellular angiotensin II induces cytosolic Ca2+ mobilization by stimulating intracellular AT1 receptors in proximal tubule cells. Am J Physiol Renal Physiol 290: F1382–F1390, 2006.




This article has been cited by other articles:


Home page
 Circ. Res.Home page
J. L. Cook, R. N. Re, D. L. deHaro, J. M. Abadie, M. Peters, and J. Alam
The Trafficking Protein GABARAP Binds to and Enhances Plasma Membrane Expression and Function of the Angiotensin II Type 1 Receptor
Circ. Res., June 20, 2008; 102(12): 1539 - 1547.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
V. P. Singh, K. M. Baker, and R. Kumar
Activation of the intracellular renin-angiotensin system in cardiac fibroblasts by high glucose: role in extracellular matrix production
Am J Physiol Heart Circ Physiol, April 1, 2008; 294(4): H1675 - H1684.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
X. C. Li and J. L. Zhuo
In vivo regulation of AT1a receptor-mediated intracellular uptake of [125I]Val5-ANG II in the kidneys and adrenals of AT1a receptor-deficient mice
Am J Physiol Renal Physiol, February 1, 2008; 294(2): F293 - F302.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
V. P. Singh, B. Le, V. B. Bhat, K. M. Baker, and R. Kumar
High-glucose-induced regulation of intracellular ANG II synthesis and nuclear redistribution in cardiac myocytes
Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H939 - H948.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
291/5/C995    most recent
00238.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (11)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baker, K. M.
Right arrow Articles by Kumar, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baker, K. M.
Right arrow Articles by Kumar, R.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2006 by the American Physiological Society.